Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 8:56 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 203 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: THC Clear all
Completed Phase 1Phase 2 Interventional Results available

Conditioning Regimen for Allogeneic Hematopoietic Stem-Cell Transplantation

NCT03513328
View directory record Official record
Conditions
Bone Marrow Failure Syndrome, Thalassemia, Sickle Cell Disease, Diamond Blackfan Anemia, Acquired Neutropenia in Newborn, Acquired Anemia Hemolytic, Acquired Thrombocytopenia, Hemophagocytic Lymphohistiocytoses, Wiskott-Aldrich Syndrome, Chronic Granulomatous Disease, Common Variable Immunodeficiency, X-linked Lymphoproliferative Disease, Severe Combined Immunodeficiency, Hurler Syndrome, Mannosidosis, Adrenoleukodystrophy
Interventions
Thiotepa--single daily dose, Thiotepa--escalated dose
Drug
Lead sponsor
University of Florida
Other
Eligibility
3 Months to 39 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 15, 2023 · Synced Oct 20, 2026, 8:56 PM EDT
Completed Phase 4 Interventional Results available

Safety and Efficacy Study of Flebogamma 5% DIF IGIV in Pediatric Subjects

NCT00634569
View directory record Official record
Conditions
Primary Immune Deficiency Disease
Interventions
Flebogamma 5% DIF
Biological
Lead sponsor
Instituto Grifols, S.A.
Industry
Eligibility
2 Years to 16 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
7
States / cities
St. Petersburg, Florida • Atlanta, Georgia • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2017 · Synced Oct 20, 2026, 8:56 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Delta-8-THC vs. Delta-9-THC on Simulated Driving Performance

NCT06218550
View directory record Official record
Conditions
Cannabis
Interventions
Delta-9-THC, Delta-8-THC, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Oct 20, 2026, 8:56 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Evaluation of Effects of CBD Products on Anxiety Among U.S. Women

NCT05108220
View directory record Official record
Conditions
Anxiety, Generalized Anxiety Disorder
Interventions
Cannabidiol (CBD)- containing consumer products
Dietary Supplement
Lead sponsor
Radicle Science
Industry
Eligibility
24 Years to 44 Years · Female only
Enrollment
1,350 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 20, 2026, 8:56 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Dronabinol in Trichotillomania and Other Body Focused Repetitive Behaviors

NCT03530800
View directory record Official record
Conditions
Trichotillomania, Skin-Picking
Interventions
Dronabinol, Placebo
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 75 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 2, 2022 · Synced Oct 20, 2026, 8:56 PM EDT
Not yet recruiting Phase 3 Interventional

Dronabinol and Epidiolex to Manage Uncontrolled Residual Symptoms of Buprenorphine Initiation Trial

NCT07148206
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Dronabinol Capsules, Epidiolex 100 mg/mL Oral Solution, Placebo Dronabinol, Placebo Epidiolex
Drug · Other
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Oct 20, 2026, 8:56 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Reward and Drug Effects on Mood and Brain Response

NCT04512365
View directory record Official record
Conditions
Cannabis Use, Healthy
Interventions
Placebo oral capsule, THC
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years to 25 Years
Enrollment
141 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 21, 2025 · Synced Oct 20, 2026, 8:56 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Cannabinoid Modulation of Pain

NCT01595620
View directory record Official record
Conditions
Pain
Interventions
Thermal, Electrical, Capsaicin, THC, Placebo
Other · Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 55 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 9, 2022 · Synced Oct 20, 2026, 8:56 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Gender Related Differences in the Acute Effects of Delta-9-Tetrahydrocannabinol in Healthy Humans: Sub-Study I

NCT02811510
View directory record Official record
Conditions
Cannabis
Interventions
Placebo, Dronabinol
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2026
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 10, 2025 · Synced Oct 20, 2026, 8:56 PM EDT
Terminated Early Phase 1 Interventional Accepts healthy volunteers

Effects of Cannabis on Cognition and Endocannabinoid Levels in Bipolar Disorder Patients and Healthy Volunteers

NCT04231643
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Dronabinol, Epidiolex, Placebos
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 50 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated May 10, 2024 · Synced Oct 20, 2026, 8:56 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

The Effects of Cannabidiol and ∆-9-THC in Humans

NCT01180374
View directory record Official record
Conditions
Healthy
Interventions
Cannabidiol, Delta-9-THC, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 55 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 31, 2022 · Synced Oct 20, 2026, 8:56 PM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Pregnenolone as a Treatment for Cannabis Intoxication

NCT07216690
View directory record Official record
Conditions
Cannabis Intoxication
Interventions
Cannabis, Pregnenolone 250 mg, Pregnenolone 500 mg, Placebo, Placebo brownie
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 20, 2026, 8:56 PM EDT
Completed Phase 1 Interventional

Antagonist-Elicited Cannabis Withdrawal

NCT01041170
View directory record Official record
Conditions
Cannabis, Dependence
Interventions
THC, Rimonobant, Rimonabant
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 45 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 20, 2026, 8:56 PM EDT
Enrolling by invitation Phase 1Phase 2 Interventional

Sequential Cadaveric Lung and Bone Marrow Transplant for Immune Deficiency Diseases

NCT01852370
View directory record Official record
Conditions
Severe Combined Immunodeficiency (SCID), Immunodeficiency With Predominant T-cell Defect, Unspecified, Severe Chronic Neutropenia, Chronic Granulomatous Disease (CGD), Hyper IgE Syndromes, Hyper IgM Deficiencies, Wiskott-Aldrich Syndrome, Mendelian Susceptibility to Mycobacterial Disease, Common Variable Immune Deficiency (CVID)
Interventions
CD3/CD19 negative allogeneic hematopoietic stem cells
Biological
Lead sponsor
Paul Szabolcs
Other
Eligibility
5 Years to 45 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2027
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Oct 20, 2026, 8:56 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Individual Differences in Drug Response

NCT03809546
View directory record Official record
Conditions
Differential Female Response to Δ9-tetrahydrocannabinol (THC)
Interventions
Dronabinol, dextrose
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 3, 2024 · Synced Oct 20, 2026, 8:56 PM EDT
Completed Phase 1 Interventional

Interleukin-2 Treatment for Wiskott-Aldrich Syndrome

NCT00774358
View directory record Official record
Conditions
Wiskott-Aldrich Syndrome (WAS), X-linked Thrombocytopenia
Interventions
Interleukin-2
Drug
Lead sponsor
Soma Jyonouchi
Other
Eligibility
24 Months and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
3
States / cities
Philadelphia, Pennsylvania • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 16, 2017 · Synced Oct 20, 2026, 8:56 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Laboratory Model of Increasing Delta-9-tetrahydrocannabinol (THC) Potency on Cigarette Smoking

NCT02961309
View directory record Official record
Conditions
Tobacco Use
Interventions
THC
Drug
Lead sponsor
Battelle Memorial Institute
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 2, 2019 · Synced Oct 20, 2026, 8:56 PM EDT
Not listed Phase 2Phase 3 Interventional

Brief Counseling to Reduce Injuries Among Emergency Department Patients Who Report Alcohol and Substance Use

NCT00547963
View directory record Official record
Conditions
Alcohol Drinking, Marijuana Smoking
Interventions
brief counseling
Behavioral
Lead sponsor
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
NIH
Eligibility
18 Years and older
Enrollment
554 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Oct 8, 2008 · Synced Oct 20, 2026, 8:56 PM EDT
Recruiting Phase 2 Interventional

Endocannabinoids in Reward

NCT07815691
View directory record Official record
Conditions
Cannabis Use Disorder
Interventions
Dronabinol, Placebo
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
21 Years to 45 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 20, 2026, 8:56 PM EDT
Completed Phase 1Phase 2 Interventional

Unrelated Hematopoietic Stem Cell Transplantation(HSCT) for Genetic Diseases of Blood Cells

NCT00730314
View directory record Official record
Conditions
Sickle Cell Disease, Thalassemia, Anemia, Granuloma, Wiskott-Aldrich Syndrome, Chediak Higashi Syndrome, Osteopetrosis, Neutropenia, Thrombocytopenia, Hurler Disease, Niemann-Pick Disease, Fucosidosis
Interventions
Hematopoietic stem cell transplantation
Procedure
Lead sponsor
Children's Hospital Los Angeles
Other
Eligibility
Up to 21 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 23, 2016 · Synced Oct 20, 2026, 8:56 PM EDT
Completed Phase 2Phase 3 Interventional

Study to Evaluate the Efficacy of Dronabinol (Marinol) as Add-On Therapy for Patients on Opioids for Chronic Pain

NCT00153192
View directory record Official record
Conditions
Chronic Pain
Interventions
Marinol (dronabinol)
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
Not listed
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 26, 2013 · Synced Oct 20, 2026, 8:56 PM EDT
Recruiting No phase listed Observational

Observational Study of THC Concentrations in Acute Cannabis-induced CNS Depression

NCT06017622
View directory record Official record
Conditions
Acute Cannabis-induced CNS Depression
Interventions
Not listed
Lead sponsor
Anebulo Pharmaceuticals
Industry
Eligibility
Not listed
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
3
States / cities
Worcester, Massachusetts • Cincinnati, Ohio • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 20, 2026, 8:56 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Trial of Cannabis for Essential Tremor

NCT03805750
View directory record Official record
Conditions
Essential Tremor
Interventions
CBD/THC, Placebo oral capsule
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
21 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Oct 13, 2022 · Synced Oct 20, 2026, 8:56 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Behavioral Pharmacology of Orally Administered THC and D-limonene

NCT06378957
View directory record Official record
Conditions
Subjective Drug Effects, THC, D-limonene
Interventions
D-Limonene, Delta-9-THC, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years to 55 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Oct 20, 2026, 8:56 PM EDT